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We present a technique which allows the detection and chromosomal localization of DNA sequence copy number
changes in solid tumor genomes from frozen sections and paraffin embedded, formalin fixed specimens. Based
on comparative genomic hybridization and on universal DNA amplification procedures this technique Is possible
even If only a few tumor cells are available. We demonstrate the feasibility of this method to visualize complete
and partial chromosome gains and losses and gene amplifications In archived solid tumor samples.
INTRODUCTION
Data about neoplasia-associated chromosome aberrations are
increasing at a rapid rate. The vast majority, however, relates
only to hematologic disorders while informations about solid
tumors are still scarce (1). Banding analyses of chromosomal
changes in solid tumors have often been hampered by low mitotic
indices and poor quality metaphase preparations. They usually
depend on cell cultures which are problematic, because secondary
changes or selective growth advantages may veil the visualization
of crucial aberrations. Moreover, the nature of many rearranged
chromosomes as well as the origin of sequences amplified in
homogeneously staining regions (HSRs) or double minute
chromosomes (DMs) cannot be established by karyotypic
analysis.
A procedure for the global screening of copy number sequence
changes within a tumor genome solely from archival tissue
material could increase our knowledge about cytogenetic
alterations in solid tumors significantly. With the vast amounts
of archival specimens available, a direct comparison of these
cytogenetic data with histological and histochemical results and
clinical follow up data would become possible. Here we present
such a technique which can be applied on paraffin embedded,
formalin fixed solid tumors even if only a small number of tumor
cells are available. It is based on the recently introduced technique
of comparative genomic hybridization (CGH) (2,3) and protocols
for universal DNA amplification (4,5).
CGH represents a new approach to screen a tumor genome
for genetic imbalances (2,3). DNA isolated from the tumor and
normal reference DNA are differentially labeled and together
hybridized to normal metaphase chromosomes under suppression
conditions with an excess of unlabeled human Cotl DNA fraction.
Detection is done with different fluorochromes, e.g. fluorescein
isothiocyanate (FTTQ for the tumor DNA and tetramethyl-
rhodamine isothiocyanate (TRITC) for the normal reference
DNA. The ratios of fluorescence intensities between FITC and
TRITC display the over- or underrepresentation of chromosome
segments in the tumor genome and thus reflect the actual copy
number of DNA sequences in the tumor genome. The technique
has already been used to detect monosomies and polysomies of
entire chromosomes or chromosomal subregions, as well as to
map gene amplifications with respect to chromosome bands
(2,3,6, own unpublished data).
Using modified protocols for DNA extraction from paraffin
embedded tissue sections and the degenerate oligonucleotide
primed PCR (DOP-PCR) (4,5) we detected chromosome gains
and losses and identified new amplification sites in solid tumors.
Some of these changes were not detected with previously
performed standard cytogenetic or molecular genetic
examinations.
RESULTS
The minimal amount of target DNA for DOP-PCR and
subsequent CGH experiments
In order to determine the relationships between template DNA
concentrations and DOP-PCR yield suitable for CGH experiments
we amplified varying amounts of total genomic DNA from
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Figure 1. DOP-PCR products revealed a typical smear ranging from 100 bp to
about 2.5 kb. A distinct band appears at 400 bp, probably representing the
amplification of repetitive DNA sequence motifs. Lane 1: 123 bp ladder, Lane
2: 10 pg template, 3: 50 pg, 4: 100 pg, 5: 25 ng, 6: 100 ng.
healthy female and male donors. A reproducible amplification
was achieved using as little as 100 pg DNA with the standard
DOP-PCR protocol (4) (Fig. 1). Fifty pg DNA were reproducibly
amplifiable, when the PCR products were ethanol precipitated
and subjected to additional rounds of amplification. Smaller
amounts of genomic DNA could not be amplified reproducibly.
CGH experiments were performed using these DOP-PCR
products together with normal male or female reference DNA.
The painting patterns of the DOP-PCR products revealed a
uniform staining of all autosomes except for heterochromatic
regions which are only weakly stained under suppression
conditions. Accordingly, the fluorescence ratios between the
fluorescence intensities of the DOP-PCR amplification products
and the normal reference DNA were within the normal range.
Only the sex chromosomes demonstrated different painting
patterns and elevated or decreased ratio values, reflecting different
sexes of the donors for the template DNA for the DOP-PCR and
the reference DNA (Fig. 2). We show that DNA amounts of 100
pg and more can be reproducibly used for DOP-PCR and
subsequent CGH experiments.
In a next step it was tested whether multiple numerical changes
of DNA copy numbers in a tumor genome after DOP-PCR of
small DNA amounts are still visible in CGH experiments. As
a model the cell line ACHN established from a renal cell
carcinoma (7) was used. This cell line was characterized by
previous G-banding analysis revealing the karyotype: 53, X, - Y ,
+der(l)t(l;10)(pl3.1;qll.2), +2, +7, +7, +12, +12, +16,
+ 17 (7). CGH analyses with DNA from this cell line had
confirmed all numerical alterations (3). CGH with the DOP-PCR
amplification product of 100 pg of this cell line DNA showed
that all numerical changes were maintained (Fig. 3A,B). A
comparison of the fluorescence ratio values for CGH using non-
amplified DNA with the DNA after DOP-PCR revealed identical
results (Fig. 4).
Analysis of paraffin embedded, formalin fixed tissues
The DNA of frozen tissue sections is still present as high
molecular weight DNA and can be subjected to DOP-PCR with
direct, standard cell lysis protocols (as described e.g. in 8). In
contrast, due to interactions of formalin between DNA and
proteins the formalin fixation is the major limiting factor for the
DNA analysis of archival material (9). Therefore we were
particularly interested to explore the suitability of DNA extracted
from paraffin embedded, formalin fixed tissues for CGH
experiments, because these materials represent the vast majority
of archival material. Usually the fixation was done with
unbuffered formalin and the exact fixation times are not known.
Paraffin embedded materials were stored up to several years
before DNA was extracted for CGH. Several reports indicate
that DNA purified from tissue fixed with unbuffered formalin
for several days shows severe degradation (9-12). Once
embedded, however, the DNA integrity of formalin fixed tissues
is well preserved even during prolonged tissue storage (9).
Several procedures for DNA preparation from paraffin
embedded tissue sections were evaluated. DNA extracted with
standard cell lysis protocols (8) did not allow an effective DOP-
PCR amplification. Use of an ion exchanger (13) could not
improve the results. Testing previously published DNA extraction
protocols from paraffin-embedded tissues (e.g. 10—13) an
additional incubation step with sodium thiocyanate after the
dewaxing improved the DNA yield and efficiency of subsequent
DOP-PCR significantly (see Material and Methods). This
protocol was used for all experiments.
To assess the influence of fixation with unbuffered formalin
on DNA a time course of fixation ranging from 0 to 48 hours
was performed using tissue obtained from a glioma. It confirmed
an increase of the DNA degradation and a decrease of the yield
of extractable DNA with the fixation time (data not shown).
Accordingly, the efficiency of DOP-PCR diminished (Fig. 5).
It therefore seemed to be unlikely that similar small amounts of
DNA could be reproducibly used for universal PCR and CGH
as with DNA obtained directly from a cell line or from frozen
tissue sections. The smallest number of formalin fixed nuclei
required for successful DOP-PCR amplification was established.
We chose cells from paraffin embedded sections which were fixed
with unbuffered formalin for at least 48 hours. These cells were
isolated (14), counted and DNA from different cell numbers
amplified. Our results indicate that generally the DNA content
of some 2000 nuclei is sufficient for amplification.
In order to test the feasibility of this approach for the diagnosis
of copy number sequence changes in different tissues, several
normal, formalin fixed, paraffin embedded tissue sections were
evaluated. This included normal tissue from kidney, testis, and
skin. All experiments yielded the expected homogeneous painting
pattern of all autosomes (data not shown).
To test the power of this technique for detection of numerical
aberrations in archival solid tumors, a glioma, classified as
anaplastic astrocytoma (grade IV), partly glioblastoma multiforme
according to the WHO classification (15) was evaluated. This
tumor was fixed with unbuffered formalin and paraffin embedded
several years ago. It had been previously characterized by banding
analyses which revealed the existence of at least two clones: 46,
XX [3 metaphases]; 47, XX, +7, +dmin [2 metaphases], and
3 metaphases with additional nonclonal losses (16). Molecular
biology investigations indicated a 20—60 fold amplification of
the EGFR gene at 7pl3 (17). DNA was extracted from the
archival tissue, 8 ng amplified with DOP-PCR, and CGH with
the amplification product performed. To rule out artifacts due
to the formalin interactions or the DOP-PCR, CGH was repeated
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Figure 2. Fluorescence ratio measurements of control CGH experiments. All ratios (FITC/TRITC) for the autosomes are within the normal range. Values outside
the normal range exist only for the sex chromosomes. Solid columns: CGH with DOP-PCR amplification product from 100 pg of normal male DNA (FITC) hybridized
together with normal female DNA (TRITC) on a male metaphase spread. The ratio (FITC/TRITC) for the X chromosomes is decreased reflecting the monosomy
X in the male reference DNA (1X:2X) while the ratio for the Y chromosome is increased (1Y:OY). Hatched columns: CGH with DOP-PCR amplification product
from 10 ng of normal male DNA (FITC) hybridized together with normal female DNA (TRTTC) on a male metaphase spread. The ratios (FITC/TRITC) for the
X and Y chromosomes are again decreased and increased, respectively. Empty columns: CGH with DOP-PCR amplification product from 100 ng of normal female
DNA (detected with FTTQ, hybridized together with normal male DNA (detected with TRITC) on a female metaphase spread. The ratio value (FTTC/TRITC) for
the X-chromosomes is now elevated.
with DNA which was directly extracted from frozen tissue of
this glioma. For both experiments Fig. 6A and B show typical
examples of normal metaphase spreads displaying pixel by pixel
ratio images. To increase the accuracy of the comparison of the
two CGH experiments FITC (tumor DNA) to TRITC (reference
DNA) combined ratio profiles for 8 and 12 metaphases,
respectively, were measured for all chromosomes (Fig. 7A,B).
Although the variability of the ratio values obtained after CGH
with the DOP-PCR amplification product was higher, in both
experiments the gain of chromosome 7 and the amplification at
7pl3 could be confirmed. Unexpectedly, two other amplification
sites at 7ql2 and Iq32, an underrepresentation of chromosome
10 and an overrepresentation of chromosome 19 were also
consistently seen in both CGH experiments Neither the two newly
identified amplification sites nor the numerical aberrations of the
chromosomes 10 and 19 had been diagnosed by previously
performed routine cytogenetic or molecular genetic studies.
DISCUSSION
We describe a procedure which allows for the first time the
establishment of a chromosomal copy number karyotype from
archival formalin fixed, paraffin embedded, solid tumors even
if only low numbers of tumor cells are available. This procedure
combines two recently introduced techniques: CGH (2,3) and
a procedure for the universal amplification of DNA, the DOP-
PCR (4,5).
CGH offers a new method to screen for genetic imbalances
and for the detection and chromosomal localization of DNA
sequence copy number changes anywhere in the tumor genome
in a single in situ hybridization (2,3). Cytogenetic analyses of
copy number differences are now possible with tumor DNA
alone. From several recently published protocols for 'universal'
DNA amplification (4,5,18,19) we chose the DOP-PCR (4,5).
While some chromosomes with higher or lower fluorescence
intensities after CGH experiments are often directly visible in
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Figure 3. CGH experiment with 100 pg of DOP-PCR amplified genomk DNA (detected with FITO from the ACHN renal cell carcinoma cell line and reference
DNA (detected with TRTTC) on a normal metaphase spread. A) In the FITC image all numerical aberrations are readily visible. B) FTTC to TRTTC pixel by pixel
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Figure 4. Comparison of fluorescence ratio values of the CGH results with DNA from the ACHN-cell line DNA as described in (3) (solid columns) and CGH
results with the DOP-PCR amplification product of 100 pg of ACHN cell line DNA (hatched columns).
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Figure 5. Influence of formalin fixation time on the DNA yield after DOP-PCR.
Lane 1: Hind m marker. Lanes 2 - 8 show the DOP-PCR amplification products
using DNA extracted from a glioma after different fixation times (0, 1, 2, 4,
8, 24, 48 hrs).
the fluorescence microscope, an accurate evaluation depends on
image acquisition using a cooled CCD camera and digital image
analysis. The software used was developed in our laboratory
particularly for the evaluation of CGH experiments (3; du Manoir
et ah, Manuscript in preparation). These programs allow the rapid
measurement of fluorescence intensity ratios along chromosomes.
The quantitative evaluations will eventually make possible
automated procedures for the assessments of gains and losses,
which will then be usable on a routine basis in many laboratories.
Due to the suppression conditions only a residual weak painting
of chromosomal regions containing repetitive DNA sequences,
e.g. centromeric regions, is achieved. This residual painting can
be more intensive either for FTTC or for TRITC within one
experiment. However, very small differences in these 'weak
painting areas' cause tremendous deviations of the ratio. Consider
for example fluorescence intensity values of 138 for FTTC and
128 for TRITC on a chromosome arm out of a gray scale ranging
from 0 to 255. This would result in a FITC/TRITC ratio of 1.08.
In contrast, at centromeric regions weak values such as 10 for
FTTC and 1 for TRITC would result in a FITC/TRITC ratio value
of 10. Depending on which fluoresence is slightly more intensive,
the ratio deviation can be in either way: in Figure 7A, FTTC is
somewhat more intensive, while in Figure 7B, TRITC has higher
intensity values at the centromeric regions. The establishment
of a copy number karyotype for these regions is impossible.
Since DNA remains as high molecular weight DNA if fresh
tissue is frozen immediately after surgical removal (9, own
unpublished data) the DNA of cells from such specimens is
directly accessible for amplification with DOP-PCR and
subsequent CGH experiments after destroying the cell membranes
with standard lysis protocols, e.g. as described in (8). In contrast
fixed and embedded materials represent a very heterogeneous
group with several factors contributing to this heterogeneity: (a)
variable lenghts of time between surgical removal of the tissue
and fixation; (b) variable levels of nucleases in different tumors;
(c) variable fixation times with unbuffered formalin (9).
Previously published protocols for DNA extraction from paraffin
embedded tissue sections (9-13) were tested and refinements
evaluated. For tissues fixed with unbuffered formalin our
experiments confirmed a significant degree of DNA degradation
over a time course of 48 hours. This degradation, however, was
not observed in tissues which were fixed with buffered formalin
(4% PBS) (own unpublished data). As described by others, the
use of ionic detergents and long periods of digestion using high
concentrations of a protease were found to be critical for success.
An additional incubation step with sodium thiocyanate, a strong
protein-denaturating agent, which dissociates DNA-nucleohistone
complexes improved the DNA yield when applied after dewaxing
(see Methodology). Sodium thiocyanate had previously been
proven to increase the hybridization efficiency of FISH on
paraffin embedded tissue sections (21).
The varying amounts of DNA from different tumors necessary
for DOP-PCR reflects the differences in DNA preservation. With
DNA directly obtained from a cell line, 50 pg are sufficient for
CGH experiments after DOP-PCR. Since the diploid DNA
content of a cell is 6.6 pg (20), our model experiments suggest
that the DNA content of about 10 unfixed cells is sufficient.
However, taking into account the DNA loss during an extraction
procedure, it is likely to assume that one might need the DNA
content of a higher cell number than 10 for reproducible DOP-
PCR with subsequent CGH. In contrast DNA from 2000 cells
was necessary for DOP-PCR in case of paraffin embedded tumors
fixed with unbuffered formalin. Assuming that a tumor of 1 cm3
may contain 109 tumor cells (22), 2000 cells would represent
a tumor size of about 1 mm3. Such a number of tumor cells can
easily be scratched from virtually all tissue sections.
In our study tissue samples were taken which microscopically
consisted solely of malignant cells. An accurate estimation of the
percentage of normal cells derived from connective tissues,
lymphocytes or blood vessels was not possible. We assume that
the percentage of tumor cells was at least 90%. Preliminary
experiments to test the maximal tolerable 'contamination' with
normal cells revealed that numerical changes such as monosomies
or trisomies are still detectable with a 50% portion of normal
cells (own unpublished data).
Although it seems unlikely that all archival tumor materials
will become analyzable by this technique due to deficiencies in
fixation and embedding protocols, we have already used this
technique to analyze successfully a variety of paraffin embedded
tissues from brain, breast, skin, testis and lung tumors (own
unpublished data). These tissues were contributed from different
laboratories, fixed with unbuffered formalin for an unspecified
time and stored from several months up to several years at room
temperature after paraffin embedding.
In many cases sufficient DNA can be extracted from a tissue
section to perform a CGH experiment even without DOP-PCR
amplification. However, the combination of DOP-PCR and CGH
will allow the analysis of genomic imbalances in tumors with
only few cells as starting material and thus make possible a
comparison of genetic changes with histological and
immunohistochemical features and evaluations of the
multiclonality of a tumor. Moreover, this procedure should prove
most valuable for the development of diagnostic tests, since
minute bioptic samples, such as fine needle aspirations, can be
investigated.
While balanced translocations will not be visible with this
technique, the easy chromosomal mapping of amplification sites
1912 Human Molecular Genetics, 1993, Vol. 2, No. 11
Figure 6. (A) FTTC to TRTTC ratio image of a normal female metaphase spread after CGH with DOP-PCR amplified DNA extracted from archival material of
a glioblastoma of a female patient; (B) FTTC to TRITC ratio image of a normal male metaphase spread after CGH with DNA extracted from fresh tissue of the
same tumor. In both experiments the tumor DNA was detected with FTTC, while normal male reference DNA was detected with TRITC. The look up table for
displaying the ratio values is presented in the left upper corner blue: range of ratio values >2 suggesting a copy number in the tumor more than twice the copy
number present in the reference genome; green: range suggesting a trisomy; white: range suggesting a disomy; red: range suggesting a monosomy; yellow: range
of ratios <0.5 suggesting a strong underrepresentation or the complete absence of chromosome material. Accordingly in both metaphase spreads the color of the
X chromosomes (expected ratio 2:1), of chromosomes 7, and of chromosomes 19 suggest a higher copy number in the glioma genome, while the color of chromosomes
10 suggests an underrepresentation. Note the yellow color of the Y chromosome in (B) reflecting the absence of this chromosome in the tumor genome. The blue
region on chromosomes 1 (arrowhead) and two blue regions on chromosome 7 (arrows) are consistently seen in these and other metaphase spreads and indicative
for the localization of DNA sequences with a highly increased copy number in the tumor genome. A detailed comparison of the colors seen along homologous chromosomes
in the two metaphase spreads demonstrates the variability of the fluorescence ratio values obtained for individual chromosomes. Accordingly, in tumors with complex
karyotypic changes it is rarely the case that all genetic imbalances can be seen in the ratio image of a single normal metaphase spread subjected to CGH. This variability
stresses the importance of a statistical analysis of a number of metaphase spreads for an unequivocal interpretation (compare Fig. 7A,B).
alone underlines the importance of this technique, since each
amplification site probably harbors genes, which are important
for the tumor initiation or progression. The identification of
overlap regions for chromosomes showing partial gains and losses
by CGH of a series of tumors will pinpoint other regions of
interest. As the development for universal PCR protocols will
progress it is likely that CGH analyses will become possible even
on a single cell basis. This might be achieved with a recently
introduced modification consisting of a DNA pretreatment with
topoisomerase I which increased the efficiency of DOP-PCR
dramatically (23).
In the glioblastoma case described above we found
abnormalities which were not detected with standard G-banding
analyses or molecular genetic studies. We anticipate that
comprehensive studies consisting of banding analyses whenever
possible, molecular genetic studies, multicolor FISH with
chromosome specific DNA probes (24-26), and CGH analyses
will improve our understanding of causative mechanisms of solid
tumors considerably. Each method provides unique data and the




Metaphase spreads were prepared from phytohemagglutinin (PHA>stimulated
lymphocytes of healthy individuals (46,XX or 46,XY) using standard procedures
of hypotonic treatment and methanol/acetic acid fixation (3:1, v/v).
Material
To obtain DNA for the control experiments and as reference DNA for CGH
experiments blood was drawn from healthy male and female donors. The cell
line ACHN was established from a papillary renal cell carcinoma (7). All paraffin
embedded tissues were evaluated by a pathologist. The glioma samples consisted
microscopically solely of malignant cells without detectable 'contaminants' of
normal tissue.
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Figure 7. Average FITC (tumor DNA) to TRTTC (reference DNA) ratio profiles. A) CGH experiment with glioma DNA extracted directly from fresh tumor (average
profile obtained from 8 metaphases); B) CGH experiment with DNA extracted from paraffin embedded, formalin fixed tissue of the same glioma tumor as in A)
after DOP-PCR (12 metaphases). Ratios along the individual chromosomes are shown on the right side of each chromosome. Left, middle and right vertical lanes
represent the lower, middle and upper limits of the normal range. Due to the suppression with Cotl DNA fraction the heterochromatic blocks Cm particular the
centromeric regions of chromosomes 1,9, 16, and the p-arms of all acrocentric chromosomes) yielded very low FITC and TRTTC fluorescence intensities resulting
in unreliable ratio values and are excluded from evaluation (detailed explanation see text). Note the ratio peaks on the q-arm of chromosome 1 and the p- and q-arms
of chromosome 7, representing amplification sites. Higher copy numbers within the tumor genome for the chromosomes 7 and X as well as the decreased copy
number for chromosome 10 are readily visible in both experiments. The consistently elevated (borderline in A) and clearly above the normal range in B) ratio values
for chromosome 19 demonstrate the existence of a chromosome 19 gain in a major subclone of this tumor.
DNA extraction procedures and cell counting
Genomic DNA was prepared from blood of healthy male and female donors and
from the cell line ACHN following standard protocols (27).
DNA extraction from formalin fixed, paraffin embedded tissues required several
modifications: Paraffin embedded tissues were incubated for several hours at 65°C.
Dewaxing was done with 3 changes of Xylol, 10 minutes each at room temperature,
and 2 changes of Methanol, 5 minutes each at room temperature. Sections
containing tumor material as diagnosed earlier by a pathologist were scratched
from the slide and transferred to in an eppendorf tube. The average size of the
scratched tumor material was about 2 to 3 mm3. The tissue was incubated
overnight in 1 ml 1 M sodium thiocyanate at 37°C.
For establishing the minimal numbers of formalin fixed nuclei for DOP-PCR,
in some cases the nuclei were isolated after the sodium thiocyanate step according
to previously published protocols (14): tissues were digested with Pepsin (4mg/ml),
adjusted to pH 2.0 with 2N HCL at 37°C. The cells were washed in distilled
water and the cell number established by counting the cells of this cell suspension
using a 'Neubauer-cell-count-chamber'.
The tissue samples or the cell suspensions after counting were then washed
twice with DNA isolation buffer (75 mM NaCl, 25 mM EDTA, 0.5% Tween
20) and 40 /d Proteinase K (10 mg/ml) added for overnight incubation at 55°C.
SDS was omitted since it reduces Taq Polymerase activity. Phenol/chloroform
DNA extraction (2 x Phenol; 2x Phenol/Chloroform; 1 x Chloroform) followed
by ethanol precipitation was done the next day.
Estimation of DNA concentration
In order to estimate the extracted DNA concentrations, 1 pd of extracted DNA
was placed on an ethidium bromide plate.
DOP-PCR
DOP-PCR was performed as described (4,5) on a Thermocycler 60 (Bio-med)
in a 50 id reaction volume (2mM MgCl2, 50 mM KC1, 10 mM TrisHCl, pH
8.4, 10 >ig/ml gelatine, 200/iM of each dNTP, 1.7 fM primer 6-MW [5'-CCG
ACT CGA GNN NNN NAT GTG G-3', with N=A,C,G, or T in approximately
equal proportions] and 2.5 U Taq polymerase [Perkin-Elmer Cetus]) with 10 min
at 93°C, followed by five cycles of 1 min at 94°C, 1.5 min at 30°C, 3 min
transition 30—72°C, and 3 min extension at 72°C, followed by 35 cycles of 1
min at 94°C, 1 min at 62°C, and 3 min at 72°C, with an addition of 1 sec/cycle
to the extension step and a final extension of 10 min.
DNA labeling
The genomic DNA and the DOP-PCR amplification products were labeled with
digoxigenin-11-dUTP or biotin-11-dUTP using standard nick-translation procedures
(28).
CGH
CGH was done as described previously (3) with minor modifications. Briefly,
100-200 ng of biotinylated tumor DNA or DOP-PCR amplification product was
mixed with the same amount of normal digoxigenin labeled reference DNA and
hybridized in the presence of 50 ^g Cotl-DNA and 50 jig sonicated salmon DNA.
Hybridization was allowed for four to five days. Probe detection was carried
out as described (3).
Image acquisition
Image acquisition and image processing were performed as detailed in (3). Briefly,
for image acquisition an epifluorescence microscope (Zeiss Axiophot) equipped
with a cooled CCD-camera (Photometries, Tucson, AZ) with the Kodak 1400
chip (1317x1035 pixels) interfaced to a Quadra 900 was used. For image
recording, a selected area of 512x512 pixels was adjusted to the optical center
of the microscope field and gray level images were taken separately for each
fluorochrome using the appropriate filter sets.
Image processing and evaluation
To define an empirical threshold for the unequivocal identification of gains or
losses, as used in Fig. 2 and 4, control CGH experiments with mixtures of biotin-
and digoxigenin-labeled control DNA (46.XY) were carried out. The mean of
the fluorescence ratio values and the limits of the 95% confidence interval (mean
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+/— 1.96 times the standard deviation of the mean) were calculated (3).
Chromosomes with fluorescence ratios outside the confidence interval were
considered to be over- or underrcpresented, respectively.
Digital images were processed wim programs developed in our laboratory (du
Manoir et al., manuscript in preparation) using the software package TCL Image
(Multihouse, Amsterdam, The Netherlands). Image shifts were corrected using
the gravity center of a designated chromosome in the DAPI, FITC, and TRITC
image, respectively. To obtain FITC to TRITC pixel by pixel ratio images of
one metaphase spread (Fig. 3B and Fig. 6A,B) a FITC image was divided (pixel
by pixel) by the TRITC image. After normalization procedures a three color
(Fig. 3B) or five color (Fig. 6A,B) look-up table was used for the visualization
of gray levels below, under or within the threshold of the normal range.
The procedure for the calculation of FTTC and TRITC mean ratio profiles
includes the following steps: Firstly, the determination of the medial axis of each
chromosome within the DAPI image as described by Kallioniemi et al. (2).
Secondly, the calculation of the FITC and TRITC profiles using a resampling
perpendicular to the medial axis and profile ratio calculations. Thirdly, for each
chromosome type an averaging of individual chromosome ratio profiles from
different metaphases. The detailed procedure will be described elsewhere
(du Manoir et al., manuscript in preparation).
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